BioPharmX Corporation (NASDAQ:BPMX) Expected to Announce Earnings of -$0.25 Per Share

Brokerages expect that BioPharmX Corporation (NASDAQ:BPMX) will report ($0.25) earnings per share for the current quarter, Zacks reports. Zero analysts have provided estimates for BioPharmX’s earnings. BioPharmX reported earnings per share of ($0.50) during the same quarter last year, which would indicate a positive year-over-year growth rate of 50%. The firm is expected to issue its next quarterly earnings results on Thursday, August 29th.

On average, analysts expect that BioPharmX will report full-year earnings of ($1.00) per share for the current year. For the next fiscal year, analysts forecast that the company will report earnings of ($0.75) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that follow BioPharmX.

BioPharmX (NASDAQ:BPMX) last posted its quarterly earnings data on Tuesday, June 11th. The company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.13).

BPMX traded down $0.09 during trading on Wednesday, hitting $0.70. The company’s stock had a trading volume of 164,429 shares, compared to its average volume of 615,241. BioPharmX has a twelve month low of $0.75 and a twelve month high of $6.75. The business’s fifty day simple moving average is $0.95.

BioPharmX Company Profile

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).

Featured Article: What is the Dividend Aristocrat Index?

Get a free copy of the Zacks research report on BioPharmX (BPMX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BioPharmX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioPharmX and related companies with's FREE daily email newsletter.